# EDGAR Filing Document

**Accession Number:** 0001781983
**File Stem:** 0001104659-26-006267
**Filing Date:** 2026-1
**Character Count:** 6906
**Document Hash:** ac51c44d0d7eaa9513fbcd11920d680e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-006267.hdr.sgml**: 20260123

**ACCESSION NUMBER**: 0001104659-26-006267

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260123

**ITEM INFORMATION**: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

**FILED AS OF DATE**: 20260123

**DATE AS OF CHANGE**: 20260123

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aprea Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001781983
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39069
- **FILM NUMBER:** 26557206

**BUSINESS ADDRESS:**
- **STREET 1:** 3805 OLD EASTON ROAD
- **CITY:** DOYLESTOWN
- **STATE:** PA
- **ZIP:** 18902
- **BUSINESS PHONE:** 215-948-4119

**MAIL ADDRESS:**
- **STREET 1:** 3805 OLD EASTON ROAD
- **CITY:** DOYLESTOWN
- **STATE:** PA
- **ZIP:** 18902

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 8-K**

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**January 23, 2026**

Date of Report (Date of earliest event reported)

------

**Aprea Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

------

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**001-39069** | &nbsp;&nbsp;**001-39069** | &nbsp;&nbsp;**84-2246769** |
| &nbsp;&nbsp;(State or other jurisdiction<br> of incorporation) | &nbsp;&nbsp; (Commission<br> File Number) | &nbsp;&nbsp; (Commission<br> File Number) | &nbsp;&nbsp; (IRS Employer<br> Identification No.) |
| &nbsp;&nbsp; **3805 Old Easton Road**<br> **Doylestown, PA**<br> (Address of principal executive offices) | &nbsp;&nbsp; **3805 Old Easton Road**<br> **Doylestown, PA**<br> (Address of principal executive offices) | &nbsp;&nbsp; <br> **18902**<br> (Zip Code) | &nbsp;&nbsp; <br> **18902**<br> (Zip Code) |

---

&nbsp;&nbsp; Registrant's telephone number, including area code: **(215) 948-4119**<br>(Former name or former address, if changed since last report): Not applicable <br>

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

------

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on** <br> **which registered**  |
| Common stock, par value $0.001 per share | APRE | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**

On January 23, 2026, Aprea Therapeutics, Inc. (the "Company") received a deficiency letter from the Nasdaq Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").

The Nasdaq deficiency letter has no immediate effect on the listing of the Company's common stock, and its common stock will continue to trade on The Nasdaq Capital Market under the symbol "APRE" at this time.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A) the Company has been provided a compliance period of 180 calendar days, or until July 22, 2026, in which to regain compliance with the minimum bid price requirement. If the Company evidences a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180-day compliance period, the Staff will provide the Company with written confirmation that is has regained compliance. In the event the Company does not regain compliance with the $1.00 bid price requirement by July 22, 2026, the Company may be eligible for consideration of a second 180-day compliance period if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq's Capital Market, other than the minimum bid price requirement. In addition, the Company would also be required to notify Nasdaq of its intent to cure the minimum bid price deficiency.

If the Company does not regain compliance with the Minimum Bid Price Requirement by the end of the compliance period (or the second compliance period, if applicable), the Company's common stock will become subject to delisting. In the event that the Company receives notice that its common stock is being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination by the Staff to a hearings panel.

The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement, including initiating a reverse stock split. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq Listing Rules.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Aprea Therapeutics, Inc.** | **Aprea Therapeutics, Inc.** |
| Dated: January 23, 2026 | By: | /s/ Oren Gilad |
|  | Name: | Oren Gilad, Ph.D. |
|  | Title: | President and Chief Executive Officer |

---